AdvanCell, a clinical-stage radiopharmaceutical company specializing in targeted alpha therapies, is expanding the scope and ...

Eli Lilly has begun the week with a bang. Early Monday morning, AdvanCell and OliX Pharmaceuticals put out news that the Big ...

Australian clinical-stage radiopharmaceutical company AdvanCell has announced an expansion to the scope and breadth of its ...

AdvanCell, a clinical-stage radiopharmaceutical company specializing in targeted alpha therapies, today announced an expansion to the scope and breadth of its strategic collaboration with Eli Lilly ...

We recently published a list of 10 Important News Updates Investors Shouldn’t Miss. In this article, we are going to take a ...

AdvanCell, an Australia-based radiopharmaceutical company, has raised $112m as investor interest in the radiopharma sector ...

AdvanCell, a clinical-stage radiopharmaceutical company developing innovative cancer therapeutics, today announced the successful completion of an oversubscribed US$112 million Series C financing.

AdvanCell, a clinical-stage radiopharmaceutical company specializing in targeted alpha therapies, today announced an expansion to the scope and breadth of its strategic collaboration with Eli Lilly ...

Eli Lilly strengthens its pipeline with AdvanCell for targeted alpha therapies and partners with OliX to advance OLX75016 for ...

The German drugmaker confirmed acquisition talks, but cautioned a deal may not materialize. Elsewhere, Biohaven got priority ...

SYDNEY, February 03, 2025--(BUSINESS WIRE)--AdvanCell, a clinical-stage radiopharmaceutical company developing innovative cancer therapeutics, today announced the successful completion of an ...

AdvanCell, a clinical-stage radiopharmaceutical company developing innovative cancer therapeutics, today announced the successful completion of an oversubscribed US$112 million Series C financing.